Equities Analysts Set Expectations for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Roth Capital issued their Q1 2026 earnings estimates for CervoMed in a report issued on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan forecasts that the company will earn ($0.52) per share for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($2.76) EPS.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.16 million for the quarter, compared to analyst estimates of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

Several other analysts have also recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of CervoMed from $12.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday. Morgan Stanley reaffirmed an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Brookline Capital Management raised shares of CervoMed from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Chardan Capital raised shares of CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Thursday, March 13th. Finally, Jones Trading raised shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Thursday, March 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, CervoMed presently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Price Performance

Shares of CRVO opened at $9.34 on Wednesday. The company’s 50-day simple moving average is $2.73 and its 200-day simple moving average is $7.87. CervoMed has a 1 year low of $1.80 and a 1 year high of $26.38.

Hedge Funds Weigh In On CervoMed

A number of hedge funds have recently modified their holdings of the business. Woodline Partners LP purchased a new position in CervoMed in the 4th quarter valued at $175,000. Nuveen Asset Management LLC increased its stake in shares of CervoMed by 113.6% during the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock worth $97,000 after acquiring an additional 22,104 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of CervoMed during the fourth quarter worth about $32,000. Mariner LLC purchased a new position in CervoMed during the fourth quarter worth about $30,000. Finally, DRW Securities LLC purchased a new position in CervoMed during the fourth quarter worth about $30,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.